Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

214
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
214
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

487
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
487
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective Cohort Study Evaluating Impact of Hemodialysis on Glycemia: BLOSSOM (Blood Sugar Sensing on Maintenance Dialysis) Cohort Findings.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
Same author

Implementation of Intermittently Scanned Continuous Glucose Monitoring and Changes in Hospitalizations and Health Care Costs in Insulin-Treated Type 2 Diabetes.

Diabetes care·2026
Same author

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.

Diabetes, obesity & metabolism·2026
Same author

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.

Diabetes care·2026
Same author

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

Hypertension (Dallas, Tex. : 1979)·2026

Related Experiment Video

Updated: May 15, 2025

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
08:16

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

1.4K

Addressing the Diabetes Tsunami Requires Expanded Access to Diabetes Technologies.

Davida F Kruger1, Christopher G Parkin2, Irl B Hirsch3

  • 1Division of Endocrinology, Diabetes, Bone & Mineral, Henry Ford Health System, Detroit, MI, USA.

Journal of Diabetes Science and Technology
|April 10, 2025
PubMed
Summary

Continuous glucose monitoring (CGM) and automated insulin delivery (AID) improve diabetes care but are often inaccessible due to restrictive insurance criteria. This review examines evidence and recommends expanding access to these life-enhancing technologies.

Keywords:
AIDCGMautomated insulin deliverycontinuous glucose monitoringinsurance

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.7K

Related Experiment Videos

Last Updated: May 15, 2025

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
08:16

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

1.4K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.5K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.7K

Area of Science:

  • Endocrinology
  • Medical Technology
  • Health Economics

Background:

  • Continuous glucose monitoring (CGM) and automated insulin delivery (AID) offer significant benefits for diabetes management.
  • These advanced technologies can enhance patient outcomes, improve quality of life, and potentially lower long-term healthcare costs.
  • However, access is frequently restricted by insurance provider eligibility criteria.

Purpose of the Study:

  • To review the evidence supporting CGM and AID use across diverse diabetes populations.
  • To analyze current insurance eligibility criteria that limit access to these technologies.
  • To propose recommendations for revising criteria to improve patient access.

Main Methods:

  • This study employed a narrative review and commentary approach.
  • Evidence supporting CGM and AID efficacy in various diabetes populations was synthesized.
  • Current insurance eligibility criteria were examined for their restrictiveness.

Main Results:

  • CGM and AID demonstrate clear benefits for individuals with diabetes.
  • Existing insurance criteria exclude many patients who could greatly benefit from these technologies.
  • There is a significant gap between the potential utility of these devices and their accessibility.

Conclusions:

  • Expanding access to CGM and AID is crucial for improving diabetes care.
  • Modifying current insurance eligibility criteria is necessary to ensure broader patient benefit.
  • Policy changes are recommended to facilitate wider adoption of these technologies.